Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maud Garnier"'
Publikováno v:
BMJ Open, Vol 11, Iss 6 (2021)
Objectives Our main objective was to describe transgender people’s reasons for consulting a general practitioner (GP) outside of transition-related issues; the secondary objective was to study the qualitative aspects of the primary care visits for
Externí odkaz:
https://doaj.org/article/06607e9af43c45e1a70540f4c1a18f84
Autor:
R. Jospe, Fabrice Zeni, Christian Auboyer, Frédéric Lucht, Bruno Pozzetto, Pascal Fascia, Maud Garnier, Philippe Berthelot, Stephane Guyomarc'h
Publikováno v:
Infection Control & Hospital Epidemiology. 28:633-636
We calculated the incidence of nosocomial infection in 2 intensive care units (ICUs) on the basis of prevalence data recorded from 1997 through 2002 and compared these estimates to cumulative incidences measured in the 2 ICUs during the same period t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29496d6e3c9d062dab75e25a45ac279e
https://doi.org/10.1086/513536
https://doi.org/10.1086/513536
Autor:
Roland Chvetzoff, Maud Garnier, Josette Chalencon, Thierry Philip, Yves Devaux, Gisèle Chvetzoff, David Pérol, Laurence Lancry
Publikováno v:
Journal of pain and symptom management. 30(6)
This study aimed to determine factors favoring home death for cancer patients in a context of coordinated home care. A retrospective study was conducted among patients followed up by the home care coordinating unit of the cancer center of Lyon. The m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::981b74e082e05cb4381b1fe3d4b367f2
https://pubmed.ncbi.nlm.nih.gov/16376739
https://pubmed.ncbi.nlm.nih.gov/16376739
Autor:
Jean-Yves Blay, Thérèse Gargi, Maud Garnier, Bertrand Coiffier, Charles Dumontet, Catherine Chassagne, David Pérol, Christelle Lenain, Françoise Berger
Publikováno v:
The hematology journal : the official journal of the European Haematology Association. 5(5)
High-dose chemotherapy and autologous marrow or peripheral stem cell support offers the best chance of cure in some subgroups of patients with non-Hodgkin’s lymphoma (NHL). Less is known about the role of a second course of myeloablative chemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b0c14b8bb69fab296888dad89b60ad
https://pubmed.ncbi.nlm.nih.gov/15448666
https://pubmed.ncbi.nlm.nih.gov/15448666